Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
April 16, 2013 11:55 ET
|
Synergy Pharmaceuticals
NEW YORK, April 16, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its...
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
April 10, 2013 20:53 ET
|
Synergy Pharmaceuticals
NEW YORK, April 10, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing of an...
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
April 09, 2013 16:34 ET
|
Synergy Pharmaceuticals
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is offering...
Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results
March 18, 2013 17:00 ET
|
Synergy Pharmaceuticals
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results...
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
March 15, 2013 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, March 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results...
Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 22, 2013 06:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President...
Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
February 11, 2013 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock...
Synergy Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 07, 2013 08:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President...
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
January 28, 2013 05:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders, announced today that oral dosing of healthy...
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
January 17, 2013 16:05 ET
|
Synergy Pharmaceuticals
NEW YORK, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously...